Tamra Srianant, PA
Physician Assistant · Englewood, CONPI 1063750719
Payments from drug & device makers
Across 332 payments — averaging $16.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$912
- Lilly USA, LLC$692
- AbbVie$420
- Boehringer Ingelheim$357
- Amneal Pharmaceuticals LLC$302
- Sanofi-aventis U.S. LLC$246
- plus $3K from 30 others
What the payments were for
- Food & beverage$5,44699%
- Education$671%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 99 | $912 |
| Lilly USA, LLC | 42 | $692 |
| AbbVie | 23 | $420 |
| Boehringer Ingelheim | 16 | $357 |
| Amneal Pharmaceuticals LLC | 18 | $302 |
| Sanofi-aventis U.S. LLC | 13 | $246 |
| Mannkind Corporation | 11 | $205 |
| Antares Pharma, Inc. | 10 | $196 |
| AstraZeneca(2 entities) | 9 | $180 |
| Radius Health, Inc. | 8 | $177 |
| Amphastar Pharmaceuticals, Inc. | 3 | $169 |
| Bayer | 7 | $151 |
| Dexcom, Inc. | 6 | $137 |
| Medtronic | 6 | $112 |
| Abbott | 5 | $111 |
| Amgen | 6 | $107 |
| IBSA Pharma Inc. | 6 | $105 |
| Currax Pharmaceuticals LLC | 7 | $102 |
| Boston Scientific | 2 | $96 |
| Recordati_rare_diseases_inc. | 4 | $94 |
| Tandem Diabetes Care, Inc. | 6 | $88 |
| Cequr Corporation | 2 | $70 |
| Pfizer | 3 | $63 |
| Ultragenyx Pharmaceutical Inc. | 3 | $58 |
| Amryt Pharma Holdings Ltd | 2 | $55 |
| Insulet Corporation | 3 | $54 |
| Halozyme Inc | 2 | $53 |
| Lifescan, Inc. | 2 | $44 |
| Neurocrine Biosciences, Inc. | 1 | $40 |
| GRT US Holding, Inc. | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Corcept Therapeutics | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $18 |
| Ascendis Pharma Endocrinology Inc | 1 | $18 |
| Clarus Therapeutics Inc. | 1 | $14 |
| BETA Bionics, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$121
How this compares
$5,513 in reported general payments places this provider in the 95th percentile of 2,849 physician assistant providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 72 | $128,318 |
| MounjaroTirzepatide | 74 | $110,806 |
| JardianceEmpagliflozin | 77 | $88,260 |
| FarxigaDapagliflozin Propanediol | 24 | $27,911 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 14 | $24,605 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 13 | $23,459 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $18,553 |
| TrulicityDulaglutide | 11 | $18,403 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $10,978 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $8,557 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 16 | $7,464 |
| Humalog Kwikpen U-100Insulin Lispro | 19 | $7,403 |
| SynthroidLevothyroxine Sodium | 54 | $6,423 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $5,344 |
| Novolog FlexpenInsulin Aspart | 18 | $3,901 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $912 | $131,55484 claims |
| Lilly USA, LLCMounjaro, Trulicity | $692 | $129,20985 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $357 | $111,72090 claims |
| AstraZenecaFarxiga | $180 | $27,91124 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $246 | $24,60514 claims |
| AbbVieSynthroid | $420 | $6,42354 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $302 | $4,532205 claims |
| PfizerLevoxyl | $63 | $1,11721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,849 physician assistant providers in Colorado.
Other physician assistant in Englewood
- Donald MooreEnglewood$246K
- Kayla StoickEnglewood$23K
- Kathryn HarrisonEnglewood$12K
- Neekan AeiniGreenwood Village$234K
- Korby HowellCortez$182K
- Heather FinlaysonLittleton$180K
- Kristen LervikDenver$131K
- Marissa Moritz-GuzikLouisville$94K
- Clayton LabaumeDurango$87K
- Emily FrischDenver$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.